Regeneron Deal Lets Sandoz Launch Eylea Biosimilar in Late 2026

Sandoz Group AG can launch Enzeevu, its biosimilar version of Regeneron Pharmaceuticals Inc.'s blockbuster eye-disease drug Eylea, by late 2026 after the companies settled their US disputes.

The deal resolves all claims and counterclaims involving Sandoz in consolidated litigation in the US District Court for the Northern District of West Virginia, according to a stipulation and proposed dismissal order filed Tuesday. The terms of the deal are confidential, according to Regeneron’s Monday statement.

The pact allows Enzeevu to enter the US market in the fourth quarter of 2026, “or earlier in certain circumstances,” Sandoz said Tuesday in a statement.

Regeneron ...